JP2022500017A5 - - Google Patents

Info

Publication number
JP2022500017A5
JP2022500017A5 JP2021512514A JP2021512514A JP2022500017A5 JP 2022500017 A5 JP2022500017 A5 JP 2022500017A5 JP 2021512514 A JP2021512514 A JP 2021512514A JP 2021512514 A JP2021512514 A JP 2021512514A JP 2022500017 A5 JP2022500017 A5 JP 2022500017A5
Authority
JP
Japan
Prior art keywords
cas9
terminal fragment
fused
fusion protein
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512514A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657711B2 (ja
JP2022500017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050111 external-priority patent/WO2020051561A1/en
Publication of JP2022500017A publication Critical patent/JP2022500017A/ja
Publication of JP2022500017A5 publication Critical patent/JP2022500017A5/ja
Priority to JP2024192680A priority Critical patent/JP7899276B2/ja
Application granted granted Critical
Publication of JP7657711B2 publication Critical patent/JP7657711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512514A 2018-09-07 2019-09-07 核酸塩基編集システムを送達するための組成物および方法 Active JP7657711B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192680A JP7899276B2 (ja) 2018-09-07 2024-11-01 核酸塩基編集システムを送達するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862728703P 2018-09-07 2018-09-07
US62/728,703 2018-09-07
US201862779404P 2018-12-13 2018-12-13
US62/779,404 2018-12-13
PCT/US2019/050111 WO2020051561A1 (en) 2018-09-07 2019-09-07 Compositions and methods for delivering a nucleobase editing system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192680A Division JP7899276B2 (ja) 2018-09-07 2024-11-01 核酸塩基編集システムを送達するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022500017A JP2022500017A (ja) 2022-01-04
JP2022500017A5 true JP2022500017A5 (cg-RX-API-DMAC7.html) 2022-09-14
JP7657711B2 JP7657711B2 (ja) 2025-04-07

Family

ID=69722796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512514A Active JP7657711B2 (ja) 2018-09-07 2019-09-07 核酸塩基編集システムを送達するための組成物および方法
JP2024192680A Active JP7899276B2 (ja) 2018-09-07 2024-11-01 核酸塩基編集システムを送達するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192680A Active JP7899276B2 (ja) 2018-09-07 2024-11-01 核酸塩基編集システムを送達するための組成物および方法

Country Status (8)

Country Link
US (2) US12529041B2 (cg-RX-API-DMAC7.html)
EP (1) EP3847254A4 (cg-RX-API-DMAC7.html)
JP (2) JP7657711B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210055733A (cg-RX-API-DMAC7.html)
CN (1) CN112969790B (cg-RX-API-DMAC7.html)
AU (1) AU2019336245B2 (cg-RX-API-DMAC7.html)
CA (1) CA3112011A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020051561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR20210055733A (ko) * 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
WO2021188840A1 (en) * 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
US12115230B2 (en) * 2020-04-09 2024-10-15 Verve Therapeutics, Inc. Base editing of ANGPTL3 and methods of using same for treatment of disease
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20230383277A1 (en) * 2020-10-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
KR20240012377A (ko) * 2021-05-28 2024-01-29 빔 테라퓨틱스, 인크. 염기 편집기의 자기-불활성화용 조성물 및 방법
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
CN117187220A (zh) * 2022-03-08 2023-12-08 中国科学院遗传与发育生物学研究所 腺嘌呤脱氨酶及其在碱基编辑中的用途
JP2025519070A (ja) 2022-05-17 2025-06-24 エンヴェロップ セラピューティクス, インコーポレイテッド 効率的in vivo送達のための組成物および方法
EP4554967A2 (en) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024097763A1 (en) * 2022-11-01 2024-05-10 Memorial Sloan-Kettering Cancer Center Intein-based sorting system and modular chimeric polypeptides
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024233941A1 (en) * 2023-05-11 2024-11-14 Massachusetts Eye And Ear Infirmary Base editing approaches to treat abca4-associated stargardt disease
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4762183A1 (en) * 2023-08-16 2026-06-24 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Systems and methods for improving safety of split intein aav mediated gene therapy
CN117568313B (zh) * 2024-01-15 2024-04-26 上海贝斯昂科生物科技有限公司 基因编辑组合物及其用途
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
IT202400011425A1 (it) * 2024-05-21 2025-11-21 Fondazione St Italiano Tecnologia Sistema di regolazione genica (tuser)
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0329734A (ja) 1989-06-20 1991-02-07 Kubota Corp ラベルプリンタ
JP2003514564A (ja) 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
US20040003420A1 (en) 2000-11-10 2004-01-01 Ralf Kuhn Modified recombinase
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
CA2439472A1 (en) 2001-02-27 2002-09-06 University Of Rochester Methods and compositions for modifying apolipoprotein b mrna editing
AU2002330714A1 (en) 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
US7300829B2 (en) 2003-06-02 2007-11-27 Applied Materials, Inc. Low temperature process for TFT fabrication
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
US20130011380A1 (en) 2009-12-18 2013-01-10 Blau Helen M Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming
WO2012004778A1 (en) 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
JP6177780B2 (ja) 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. スプリットインテインおよびその使用
CN103088008B (zh) 2011-10-31 2014-08-20 中国科学院微生物研究所 胞苷脱氨酶及其编码基因和它们的应用
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
PT2877490T (pt) 2012-06-27 2019-02-12 Univ Princeton Inteínas clivadas, conjugados e suas utilizações
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
WO2014186686A2 (en) 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
EP3603679B1 (en) 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ CRISPR/Cas系を用いるゲノム編集の治療用の使用
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3613854A1 (en) 2014-03-05 2020-02-26 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2015298571B2 (en) * 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US20170239294A1 (en) 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
EP3212221B1 (en) 2014-10-29 2023-12-06 Massachusetts Eye & Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
JP6153180B2 (ja) 2014-11-04 2017-06-28 国立大学法人神戸大学 脱塩基反応により標的化したdna配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体
MA40921A (fr) 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
CN106011104B (zh) 2015-05-21 2019-09-27 清华大学 利用拆分Cas系统进行基因编辑和表达调控方法
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
EP3957731A1 (en) 2015-07-15 2022-02-23 Rutgers, The State University of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2999070A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
US11008555B2 (en) 2015-09-17 2021-05-18 The Regents Of The University Of California Variant Cas9 polypeptides comprising internal insertions
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11866727B2 (en) 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
WO2017093804A2 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
WO2017132580A2 (en) 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
CA3020993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
CA3034089A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
MX2019005277A (es) 2016-11-04 2019-09-27 Bluebird Bio Inc Composiciones de celulas t con car anti-bcma.
US11180778B2 (en) 2016-11-11 2021-11-23 The Regents Of The University Of California Variant RNA-guided polypeptides and methods of use
CN107043779B (zh) 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
JP7383478B2 (ja) 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
KR102569848B1 (ko) 2016-12-23 2023-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3565608A4 (en) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
WO2018152197A1 (en) 2017-02-15 2018-08-23 Massachusetts Institute Of Technology Dna writers, molecular recorders and uses thereof
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CN106916852B (zh) 2017-04-13 2020-12-04 上海科技大学 一种碱基编辑系统及其构建和应用方法
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
KR102678809B1 (ko) 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
WO2018226602A1 (en) 2017-06-05 2018-12-13 Research Institute At Nationwide Children's Hospital Enhanced modified viral capsid proteins
CN111328290A (zh) 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019040650A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
IL316453A (en) 2017-10-06 2024-12-01 Univ Oregon Health & Science RNA editing agents and methods
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
AR114014A1 (es) 2017-12-22 2020-07-08 Inst Genetics & Developmental Biology Cas Sistema de edición de bases y método basado en proteína cpf1
US20210363518A1 (en) 2018-03-19 2021-11-25 University Of Massachusetts Modified guide rnas for crispr genome editing
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR102853088B1 (ko) 2018-05-11 2025-09-02 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
KR102959497B1 (ko) 2018-05-11 2026-05-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
KR102894715B1 (ko) 2018-08-03 2025-12-03 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
WO2020041751A1 (en) 2018-08-23 2020-02-27 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
US11530245B2 (en) 2018-08-31 2022-12-20 Washington University Split intein mediated polymerization and production of mussel foot adhesive protein materials
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
CN109295186B (zh) 2018-09-30 2023-10-03 中山大学 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
CA3116606A1 (en) 2018-10-15 2020-04-23 Fondazione Telethon Intein proteins and uses thereof
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
EP3887521A1 (en) 2018-11-29 2021-10-06 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US11667682B2 (en) 2018-12-13 2023-06-06 Washington University Split intein mediated protein polymerization for microbial production of materials
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
AU2020216484A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
US20220098593A1 (en) 2019-02-13 2022-03-31 Beam Therapeutics Inc. Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CN114040970B (zh) 2019-02-13 2024-09-27 比姆医疗股份有限公司 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗
US20220127594A1 (en) 2019-02-13 2022-04-28 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
CN114096666B (zh) 2019-02-13 2025-03-18 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
EP3924479A4 (en) 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
KR102129377B1 (ko) 2019-02-21 2020-07-02 성균관대학교산학협력단 특정 특성이 발현된 단백질을 암호화하는 플라스미드를 선별하는 유도 플라스미드 디스플레이 시스템
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP7679309B2 (ja) 2019-05-10 2025-05-19 ビーム セラピューティクス インク. B型肝炎を治療するための組成物及び方法
WO2020236982A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Aav delivery of nucleobase editors
JP7679311B2 (ja) 2019-05-21 2025-05-19 ビーム セラピューティクス インク. プログラム可能塩基エディターシステムを用いた一塩基多型編集法
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
AU2020322021A1 (en) 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
KR102258713B1 (ko) 2019-07-31 2021-05-31 한양대학교 산학협력단 사이토신 염기교정용 조성물 및 이의 용도
CN119913134A (zh) 2019-08-29 2025-05-02 比姆医疗股份有限公司 用于编辑突变以允许转录或表达的组合物和方法
US20220290121A1 (en) 2019-08-30 2022-09-15 The General Hospital Corporation Combinatorial Adenine and Cytosine DNA Base Editors
AU2020344547A1 (en) 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same
AU2020466994B2 (en) 2019-09-17 2026-05-28 Rutgers, The State University Of New Jersey Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof
CN114667293A (zh) 2019-09-24 2022-06-24 Mvrix株式会社 抗病毒活性增强的纳米穿孔器
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
US11591607B2 (en) 2019-10-24 2023-02-28 Pairwise Plants Services, Inc. Optimized CRISPR-Cas nucleases and base editors and methods of use thereof
CN114867852A (zh) 2019-10-30 2022-08-05 成对植物服务股份有限公司 V型crispr-cas碱基编辑器及其使用方法
EP4061940A4 (en) 2019-11-22 2024-10-23 Flagship Pioneering Innovations VI, LLC RECOMBINASE COMPOSITIONS AND METHODS OF USE
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
GB201918693D0 (en) 2019-12-18 2020-01-29 Univ Southampton Peptide
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
AU2021232005A1 (en) 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
BR112022017735A2 (pt) 2020-03-05 2022-11-29 Flagship Pioneering Innovations Vi Llc Métodos e composições de supressão de defesa de hospedeiro para modular um genoma
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
EP3885440A1 (en) 2020-03-26 2021-09-29 Splicebio, S.L. Split inteins and their uses
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
WO2021209574A1 (en) 2020-04-15 2021-10-21 Fondazione Telethon Constructs comprising inteins
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
EP4179079A1 (en) 2020-07-10 2023-05-17 Horizon Discovery Limited Method for producing genetically modified cells
JP7890972B2 (ja) 2020-07-15 2026-07-15 ライフ エディット セラピューティクス,インコーポレイティド ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
EP4211235A2 (en) 2020-09-11 2023-07-19 Lifeedit Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
US20230383277A1 (en) 2020-10-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
IT202000028688A1 (it) 2020-11-27 2022-05-27 Consiglio Nazionale Ricerche Varianti della citidina deaminasi per l’editazione di basi
EP4274902A4 (en) 2021-01-05 2025-04-16 Revvity Discovery Limited Guide RNA designs and complexes for tracless V-CAS systems
US20240060088A1 (en) 2021-01-05 2024-02-22 Horizon Discovery Limited Guide RNA Designs and Complexes for Type V Cas Systems
CA3207144A1 (en) 2021-01-05 2022-07-14 Horizon Discovery Limited Method for producing genetically modified cells
WO2022150706A2 (en) 2021-01-08 2022-07-14 The General Hospital Corporation Genome editing approaches to treat spinal muscular atrophy
JP2024507533A (ja) 2021-02-19 2024-02-20 ビーム・セラピューティクス・インコーポレイテッド 遺伝子治療のための組み換え狂犬病ウイルス
BR112023019539A2 (pt) 2021-03-26 2023-12-05 Beam Therapeutics Inc Variantes de adenosina desaminase e usos das mesmas
CN113813398B (zh) 2021-04-23 2023-11-07 天津医科大学 一种向表面富含神经节苷脂的细胞递送重组蛋白质的方法
WO2023279118A2 (en) 2021-07-02 2023-01-05 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
CA3225808A1 (en) 2021-07-16 2023-01-19 David R. Liu Context-specific adenine base editors and uses thereof
CN113480613B (zh) 2021-08-04 2022-04-15 江南大学 一种自剪切蛋白标签、改造方法及其应用
CN113735941B (zh) 2021-08-13 2024-01-30 江南大学 一种蛋白纯化方法及其应用
EP4396207A4 (en) 2021-09-03 2025-07-16 Univ Chicago POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS
GB2702733A (en) 2021-09-22 2026-06-24 Verve Therapeutics Inc Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease
US20230105319A1 (en) 2021-09-24 2023-04-06 Crispr Therapeutics Ag PRODRUG INCORPORATED sgRNA SYNTHESIS
WO2023125814A1 (zh) 2021-12-29 2023-07-06 华东师范大学 腺嘌呤脱氨酶及其应用
WO2023155901A1 (en) 2022-02-17 2023-08-24 Correctsequence Therapeutics Mutant cytidine deaminases with improved editing precision
CN114634923B (zh) 2022-04-07 2024-02-23 尧唐(上海)生物科技有限公司 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
JP2025517515A (ja) 2022-05-26 2025-06-05 ユーシービー バイオファルマ エスアールエル 新規核酸編集タンパク質
EP4540378A1 (en) 2022-06-20 2025-04-23 CRISPR Therapeutics AG Base editing proteins and uses thereof
JP2025520697A (ja) 2022-06-23 2025-07-03 ビーエーエスエフ アグリカルチュラル ソリューションズ ユーエス エルエルシー 多様化塩基編集
AU2023325079A1 (en) 2022-08-16 2025-02-13 President And Fellows Of Harvard College Evolved cytosine deaminases and methods of editing dna using same
WO2024063273A1 (en) 2022-09-23 2024-03-28 Institute For Basic Science Novel adenine deaminase variants and a method for base editing using the same
CN120435553A (zh) 2022-09-26 2025-08-05 比姆医疗股份有限公司 合成多肽及其用途
WO2024179426A2 (en) 2023-02-28 2024-09-06 Accuredit Therapeutics (Suzhou) Co., Ltd. Deaminases for use in base editing
WO2024226156A1 (en) 2023-04-27 2024-10-31 University Of Massachusetts Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency
KR20260007576A (ko) 2023-04-28 2026-01-14 빔 테라퓨틱스, 인크. 변형된 가이드 rna
CN121889499A (zh) 2023-06-15 2026-04-17 比姆医疗股份有限公司 用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物
CN117965505A (zh) 2023-06-28 2024-05-03 微光基因(苏州)有限公司 工程化的腺苷脱氨酶及碱基编辑器

Similar Documents

Publication Publication Date Title
JP2025028857A5 (cg-RX-API-DMAC7.html)
JP2021176301A (ja) 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
CA2337100A1 (en) Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same
JP2023518596A5 (cg-RX-API-DMAC7.html)
KR20150008852A (ko) 계면활성제 펩타이드의 제조 방법
RU2012106148A (ru) Вариантные формы уратоксидазы и их применение
JP2022530917A (ja) リシン誘導体を効率的に導入するアミノアシル-tRNAシンテターゼ
RU2000103824A (ru) Адипоцит-специфические белковые гомологи
JP2024540639A5 (cg-RX-API-DMAC7.html)
Kim et al. Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent
US12509665B2 (en) Thioredoxin mutant, preparation method thereof, and application thereof in production of recombinant fusion protein
CN104387473B (zh) 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP
JP3957630B2 (ja) 組換えヒト副甲状腺ホルモンを生産する形質転換酵母及び該ホルモンの生産方法
Li et al. Feasability of Introducing a Thioether Ring in Vasopressin by nisBTC Co-expression in Lactococcus lactis
CA2390049A1 (en) Control of post-transcriptional gene silencing in plants
JP5450985B2 (ja) 真核細胞において組換えタンパク質を細胞外に放出させるためのポリヌクレオチド
CN102348800B (zh) 融合蛋白、其制备方法及其在重组蛋白表达系统中的应用
Emery et al. The p24 family of transmembrane proteins at the interface between endoplasmic reticulum and Golgi apparatus
CN109136209B (zh) 肠激酶轻链突变体及其应用
CN110387366A (zh) 一种aep环化酶在毕赤酵母中的表达方法及其应用
Yang et al. Modification and characterization of a new recombinant marine antimicrobial peptide N2
CN109689693B (zh) 提高基因编辑效率的方法和系统
JP2023528996A (ja) インスリンアスパルト誘導体およびその製造方法と使用
JP2002538775A5 (cg-RX-API-DMAC7.html)
KR101582655B1 (ko) 광활성 메티오닌 모사체 표지 단백질 생합성을 위한 메티오닐 tRNA 합성효소 변이체